Gata4 and Sp1 regulate expression of the erythropoietin receptor in cardiomyocytes

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 9, 2011, Pages 1963-1972

  von Salisch, Sandy ^a,b   Klar, Martin ^a   Thurisch, Boris ^a   Bungert, Jörg ^c   Dame, Christof ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cardioprotection; Erythropoietin; Erythropoietin receptor; GATA4; Transcription

Indexed keywords

DOXORUBICIN; ERYTHROPOIETIN RECEPTOR; GATA4 PROTEIN, MOUSE; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR SP1;

ANIMAL; ARTICLE; C57BL MOUSE; CARDIOMYOPATHY; CELL LINE; CYTOLOGY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE LOCUS; GENETICS; HEART MUSCLE; HEART MUSCLE CELL; METABOLISM; MOUSE; PROMOTER REGION; PROTEIN BINDING; RNA INTERFERENCE; TRANSGENIC MOUSE;

ANIMALS; CARDIOMYOPATHIES; CELL LINE; DISEASE MODELS, ANIMAL; DOXORUBICIN; GATA4 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; GENETIC LOCI; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, ERYTHROPOIETIN; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR;

MURINAE; MUS; MUS MUSCULUS;

EID: 80052150421     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01193.x     Document Type: Article

References (47)

1. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci. 2008; 29: 258-67.
2. Fandrey J. A cordial affair-erythropoietin and cardioprotection. Cardiovasc Res. 2006; 72: 1-2.
3. Li L, Takemura G, Li Y, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation. 2006; 113: 535-43.
4. Shan X, Xu X, Cao B, et al. Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury. Int J Cardiol. 2009; 134: 384-92.
5. Bisping E, Ikeda S, Kong SW, et al. Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure. Proc Natl Acad Sci USA. 2006; 103: 14471-6.
6. Oka T, Maillet M, Watt AJ, et al. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res. 2006; 98: 837-45.
7. Aries A, Paradis P, Lefebvre C, et al. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA. 2004; 101: 6975-80.
8. Dorn GW 2nd. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol. 2009; 6: 283-91.
9. Mehta JL. Erythropoietin in cardioprotection: does it have a future or is it all in the past? Cardiovasc Res. 2008; 79: 549-50.
10. Unger EF, Thompson AM, Blank MJ, et al. Erythiopoiesis-stimulating agents - time for a reevaluation. N Engl J Med. 2010; 362: 189-92.
11. Wu H, Lee SH, Gao J, et al. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999; 126: 3597-605.
12. Yu X, Lin CS, Costantini F, et al. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood. 2001; 98: 475-7.
13. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003; 308: 990-4.
14. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev. 1998; 52: 235-49.
15. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003; 108: 79-85.
16. Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004; 18: 1031-3.
17. Tada H, Kagaya Y, Takeda M, et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res. 2006; 71: 466-77.
18. Asaumi Y, Kagaya Y, Takeda M, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation. 2007; 115: 2022-32.
19. Youssoufian H, Longmore G, Neumann D, et al. Structure, function, and activation of the erythropoietin receptor. Blood. 1993; 81: 2223-36.
20. Zon LI, Youssoufian H, Mather C, et al. Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc Natl Acad Sci USA. 1991; 88: 10638-41.
21. Chiba T, Ikawa Y, Todokoro K. GATA-1 transactivates erythropoietin receptor gene, and erythropoietin receptor-mediated signals enhance GATA-1 gene expression. Nucleic Acids Res. 1991; 19: 3843-8.
22. Chin K, Oda N, Shen K, et al. Regulation of transcription of the human erythropoietin receptor gene by proteins binding to GATA-1 and Sp1 motifs. Nucleic Acids Res. 1995; 23: 3041-9.
23. Kirschner KM, Hagen P, Hussels CS, et al. The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells. FASEB J. 2008; 22: 2690-701.
24. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene. 2002; 21: 3368-76.
25. Zhou B, Ma Q, Rajagopal S, et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature. 2008; 454: 109-13.
26. Claycomb WC, Lanson NA Jr, Stallworth BS, et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA. 1998; 95: 2979-84.
27. Thurisch B, Liang SY, Sarioglu N, et al. Transgenic mice expressing small interfering RNA against Gata4 point to a crucial role of Gata4 in the heart and gonads. J Mol Endocrinol. 2009; 43: 157-69.
28. Wallach I, Zhang J, Hartmann A, et al. Erythropoietin-receptor gene regulation in neuronal cells. Pediatr Res. 2009; 65: 619-24.
29. Weidenfeld J, Shu W, Zhang L, et al. The WNT7b promoter is regulated by TTF-1, GATA6, and Foxa2 in lung epithelium. J Biol Chem. 2002; 277: 21061-70.
30. Valin A, Cook JD, Ross S, et al. Sp1 and Sp3 regulate transcription of the cyclin-dependent kinase 5 regulatory subunit 2 (p39) promoter in neuronal cells. Biochim Biophys Acta. 2009; 1789: 204-11.
31. Youssoufian H, Lodish HF. Transcriptional inhibition of the murine erythropoietin receptor gene by an upstream repetitive element. Mol Cell Biol. 1993; 13: 98-104.
32. Youssoufian H. Further characterization of cis-acting regulatory sequences in the genomic locus of the murine erythropoietin receptor: evidence for stage-specific regulation. Blood. 1994; 83: 1428-35.
33. Maouche L, Cartron JP, Chretien S. Different domains regulate the human erythropoietin receptor gene transcription. Nucleic Acids Res. 1994; 22: 338-46.
34. Scholz H, Wagner KD, Wagner N. Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation. Pflugers Arch. 2009; 458: 315-23.
35. Pikkarainen S, Tokola H, Kerkela R, et al. Transcription factors in the developing and adult heart. Cardiovasc Res. 2004; 63: 196-207.
36. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006; 107: 1892-5.
37. Kirkeby A, van Beek J, Nielsen J, et al. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods. 2007; 164: 50-8.
38. Fluck CE, Miller WL. GATA-4 and GATA-6 modulate tissue-specific transcription of the human gene for P450c17 by direct interaction with Sp1. Mol Endocrinol. 2004; 18: 1144-57.
39. Morrisey EE, Tang Z, Sigrist K, et al. GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. Genes Dev. 1998; 12: 3579-90.
40. Hall JL, Grindle S, Han X, et al. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics. 2004; 17: 283-91.
41. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339: 900-5.
42. Kim Y, Ma AG, Kitta K, et al. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol. 2003; 63: 368-77.
43. Liang Q, Wiese RJ, Bueno OF, et al. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol. 2001; 21: 7460-9.
44. Suzuki YJ, Nagase H, Day RM, et al. GATA-4 regulation of myocardial survival in the preconditioned heart. J Mol Cell Cardiol. 2004; 37: 1195-203.
45. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA. 1994; 91: 3974-8.
46. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-32.
47. Heberlein C, Fischer KD, Stoffel M, et al. The gene for erythropoietin receptor is expressed in multipotential hematopoietic and embryonal stem cells: evidence for differentiation stage-specific regulation. Mol Cell Biol. 1992; 12: 1815-26.